CanSino Biologics Balance Sheet Health
Financial Health criteria checks 4/6
CanSino Biologics has a total shareholder equity of CN¥5.3B and total debt of CN¥2.5B, which brings its debt-to-equity ratio to 46.5%. Its total assets and total liabilities are CN¥9.3B and CN¥4.0B respectively.
Key information
46.5%
Debt to equity ratio
CN¥2.46b
Debt
Interest coverage ratio | n/a |
Cash | CN¥4.13b |
Equity | CN¥5.29b |
Total liabilities | CN¥4.03b |
Total assets | CN¥9.32b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6185's short term assets (CN¥5.2B) exceed its short term liabilities (CN¥2.6B).
Long Term Liabilities: 6185's short term assets (CN¥5.2B) exceed its long term liabilities (CN¥1.5B).
Debt to Equity History and Analysis
Debt Level: 6185 has more cash than its total debt.
Reducing Debt: 6185's debt to equity ratio has increased from 29.9% to 46.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6185 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 6185 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.